Galen Second Read

by Ibex Medical Analytics  · Based in United States → — Transforming cancer diagnostics with AI.
Oncology Pathology Urology

Contact for pricing
Regulatory Status Disclosed

Overview

Galen™ Second Read™, now known as Ibex Prostate Detect in the US, is a software-only device developed by Ibex Medical Analytics. It is designed to analyze scanned histopathology whole slide images (WSIs) from prostate core needle biopsies (PCNB) prepared from hematoxylin & eosin (H&E) stained formalin-fixed paraffin embedded (FFPE) tissue. The tool’s primary purpose is to identify cases initially diagnosed as benign for further review by a pathologist.

Utilizing advanced AI algorithms, Galen™ Second Read™ detects tissue morphology suspicious for prostate adenocarcinoma (AdC), providing case- and slide-level alerts which include heatmaps highlighting areas likely to contain cancer. This functionality acts as a crucial safety net, assisting pathologists in ensuring accurate and timely diagnoses, enhancing diagnostic accuracy, streamlining workflows, and ultimately improving patient outcomes. The platform is deployed globally in routine clinical use, supporting pathologists in managing increasing workloads and diagnostic complexities.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-powered analysis of whole slide images (WSIs)
  • Detection of prostate adenocarcinoma (AdC)
  • Identification of potentially missed cancers
  • Case- and slide-level alerts for suspicious findings
  • Heatmaps to highlight areas likely to contain cancer
  • Quality control system for pathology diagnoses
  • Enhances diagnostic accuracy and consistency
  • Streamlines pathology workflows and improves efficiency
  • Cloud-hosted solution for accessibility
  • Supports pathologists in managing increasing diagnostic workloads

Use Cases

  • Second read system for prostate cancer diagnosis
  • Quality control in pathology laboratories
  • Assisting pathologists in identifying small and rare prostatic cancers
  • Improving diagnostic accuracy and consistency in prostate biopsies
  • Reducing turnaround times for prostate cancer diagnosis
  • Empowering pathologists to manage increasing diagnostic workloads effectively

What Physicians Need to Know

Key Capabilities
Galen™ Second Read™ (now known as Ibex Prostate Detect in the US) is a software-only device that analyzes scanned histopathology whole slide images (WSIs) from prostate core needle biopsies (PCNB) stained with hematoxylin & eosin (H&E). It identifies cases initially diagnosed as benign for further review by a pathologist. If the system detects tissue suspicious for prostate adenocarcinoma (AdC), it provides case- and slide-level alerts, including a heatmap that directs the pathologist to areas likely to contain cancer. The platform also offers automated quality control, flagging discrepancies between the algorithm's assessment and the pathologist's diagnosis. It can detect and grade cancer, as well as identify other clinically relevant features such as Gleason grading, tumor sizing, and perineural invasion.
Clinical Utility
Galen™ Second Read™ acts as a safety net for pathologists, helping to catch missed cancers in prostate biopsies. It has been shown to improve diagnostic accuracy and efficiency, reduce turnaround times, and enhance physician confidence. Studies have demonstrated its ability to identify positive cases (cancer, including AdC, ASAP, and other rare cancer subtypes) that may have been missed during the initial read. The use of AI in this second-read capacity has been shown to reduce the false-negative rate. The system can also contribute to lower pathology workloads and a better user experience.
Integration Options
The Ibex platform, which includes Galen™ Second Read™, is designed for seamless integration with third-party digital pathology software solutions, scanning platforms, and laboratory information systems (LIS). It is interoperable, allowing AI insights to be accessible from preferred image management systems. The system is cleared for use with the Philips Ultra Fast Scanner.
Compliance Status
Galen™ Second Read™ (now Ibex Prostate Detect) is cleared by the FDA as a Class II software algorithm device to assist users in digital pathology (K241232). This clearance is specific to the stated indication and to the United States. Other solutions within the Ibex platform are CE-IVD certified (per IVDR framework) and registered with regulatory bodies in the UK (MHRA), Australia (TGA), and Brazil (ANVISA). Ibex also holds quality and security certifications including HITRUST, Cyber Essentials Plus, ISO 27001, and ISO 13485.
Pricing Model
The pricing model is paid.
User Experience
The system is designed to enhance physician confidence and patient safety. It aims for a better user experience and can lead to faster diagnosis. The AI provides alerts and heatmaps for cancer detection and grading. The software is intuitive and easy to use.
Support Quality
The Ibex platform is developed by pathologists for pathologists. The company emphasizes empowering physicians and supporting pathologists.
Implementation Complexity
While designed for integration, connecting with legacy lab systems can be a complex IT project requiring dedicated resources. The system requires a minimum 20 Mbps internet connection.
Evidence Base
The Galen™ Prostate AI algorithm has shown high diagnostic accuracy for cancer detection with an AUC of 0.994 (95% CI: 0.988–0.997) in a validation set. It demonstrated 96.7% specificity and 96.6% sensitivity for prostate cancer detection. For distinguishing Gleason Grade Group 1 from Grade Group 2+, it achieved 82.1% specificity and 81.1% sensitivity. In a retrospective clinical study, pathologists using the software achieved a sensitivity of 36.3% in catching cancers that would have otherwise been missed in cases initially diagnosed as benign. The system achieved a positive predictive value (PPV) of 99.6% for heatmap accuracy. Pathologists diagnosing without AI missed 13% of cancer cases that were identified by the AI. The algorithm has been implemented in routine clinical use as a second-read system, processing over 122,000 slides and 9,200 cases over 3 years, with an overall AI Impact™ factor of 1.8%. The algorithms are trained on extensive datasets, including over 10 million slides from multiple pathology institutes.
Physician Tip

Galen™ Second Read™ (Ibex Prostate Detect) is intended as a quality-control second read, not a primary diagnostic tool. Pathologists should use the system to review flagged cases and areas of interest, but the final diagnosis should be based on the pathologist's assessment and not solely on the AI output. Be aware that while the system improves sensitivity for missed cancers, there can be a slight decrease in overall specificity. Local validation remains the responsibility of the user.

The Ibex platform is designed to integrate with various digital pathology components, including whole slide imaging (WSI) scanners, image management systems (IMS), and laboratory information systems (LIS). It is currently cleared for use with the Philips Ultra Fast Scanner. Ensure your internet connection meets the minimum requirement of 20 Mbps for optimal performance.

Details

Category Oncology AI, Pathology AI
Pricing Contact for pricing — Contact vendor for detailed pricing plans.
DeploymentCloud-hosted
Compliance
BAA Available Yes AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated

Galen™ Second Read™ received U.S. Food and Drug Administration (FDA) 510(k) clearance (K241232) on February 10, 2025, under its current name, Ibex Prostate Detect. It is cleared as an in vitro diagnostic medical device that uses AI to generate heatmaps identifying small and rare missed prostatic cancers, serving as a safety net for pathologists.

Integrations
EHR Not specified
Specialties Oncology, Pathology, Urology

FDA clearance history

This product’s FDA authorization. From FDA’s list of AI-enabled medical devices; each number links to FDA’s record.

Decision dateNumberName as listed by FDA
2025-01-24K241232 510(k)Galen™ Second Read™

What the Web Says

Galen Second Read, now known as Ibex Prostate Detect in the US, is an AI-powered digital pathology solution designed to assist pathologists in detecting prostate cancer from whole slide images of biopsies. It functions as a quality control system, performing a "second read" after initial pathologist review and flagging discrepancies or potentially missed cancers. The system has received FDA 510(k) clearance and has demonstrated high accuracy in identifying cancer and distinguishing tumor grades, with studies showing it can detect cases initially missed by pathologists.

Overall: Positive

Strengths

  • Acts as a safety net, identifying cancer cases potentially missed during initial pathologist review.
  • Improves diagnostic accuracy and safety by providing alerts and heatmaps for cancer, Gleason scores, and other indicators.
  • Increases efficiency and addresses the shortage of pathologists by streamlining the review process.
  • Demonstrated high sensitivity and specificity for cancer detection in validation studies.
  • Achieved a 99.6% positive predictive value for heatmap accuracy.
  • Can distinguish between low-grade and high-grade tumors with high accuracy.

Limitations

  • FDA clearance is specific to the stated indication and to the United States, and local validation is still required.
  • May generate false-positive alerts that necessitate additional pathologist review.
  • Limitations in external validation studies, such as the need for site-specific technical calibration and reporting performance at the prostate region level rather than patient level.
  • Challenges remain regarding scanner variability, staining heterogeneity, rare diagnoses with limited training data, and medico-legal questions about liability when algorithms miss critical diagnoses.
  • Potential for inequitable performance in under-represented patient populations.

Based on reviews from: physicianaihandbook.com, ibex-ai.com, frontiersin.org, researchgate.net, digitalpathologyassociation.org, bmj.com, pathologyai.org, aihealthindex.io, medpath.com, targetedonc.com, scilit.com, utmb.edu

Last updated: 2026-10-30

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Galen Second Read

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

fda.gov
Galen™ Second Read™ 510(k) Summary
Galen™ Second Read™ is a software-only device intended to analyze scanned histopathology whole slide images from prostate core needle biopsies to identify cases initially diagnosed as benign for further review by a pathologist. It provides case- and slide-level alerts if it detects tissue morphology suspicious for prostate adenocarcinoma.
2025-01-24
innolitics.com
The Arc From 1999 to April 2026
Ibex Medical Analytics (Galen Second Read, K241232, January 2025) became the first 510(k) to clear under the QPN product code, which was established by Paige Prostate. This demonstrates that once a De Novo establishes a regulatory slot, subsequent devices can enter through substantial equivalence.
2026-04-28
aihealthcarenow.com
FDA-Cleared AI
Galen™ Second Read™ by Ibex Medical Analytics Ltd. received FDA clearance on January 24, 2025, under submission number K241232.
2026-10-24
reachmd.com
Medical AI Diagnostic Benchmark Hub
Galen™ Second Read™ by Ibex Medical Analytics, Ltd. is listed with FDA# K241232, with evidence pending regarding its sensitivity and specificity in pathology.
2026-06-26
xrayinterpreter.com
Galen™ Second Read™
Galen™ Second Read™ is a cloud-hosted software that uses a deep convolutional neural network to analyze digitized whole slide images from H&E-stained prostate biopsies, providing binary likelihood classification for prostate adenocarcinoma and heatmaps.
2025-01-24
xiahepublishing.com
A Lifecycle Framework for Digital Pathology Implementation: Integrating Infrastructure, Workflow, Regulatory Compliance, and AI Readiness for Sustainable Adoption
Ibex Galen™ Second Read™ is an FDA-cleared AI-powered digital pathology software algorithm that assists in detecting prostate cancer on whole-slide images.
2026-06-08
innolitics.com
Ground Truth in AI/ML Medical Devices: A Practical Guide to Ground Truth Construction
For Galen™ Second Read™ (K241232), the ground truth determination for a slide was performed by two independent expert pathologists, with a third independent expert pathologist reviewing slides where there was disagreement.
2025-09-20
researchgate.net
AI in prostate cancer: a review of current applications and future directions
The Galen™ Second Read™ (also referred to as Ibex Prostate Detect) was cleared by the FDA on January 24, 2025, as a software-only device to assist pathologists in analyzing prostate biopsies.
2025-01-24

Videos

Product demos, reviews, and walkthroughs for Galen Second Read.

Loading videos...

View all on YouTube

Frequently Asked Questions

Galen™ Second Read™ (now known as Ibex Prostate Detect in the US) is an AI-powered digital pathology solution designed to assist pathologists in detecting prostate cancer from tissue biopsies. It functions as a 'second read' system, analyzing whole slide images of prostate core needle biopsies that were initially diagnosed as benign by a pathologist. If the AI identifies suspicious morphology, it generates case- and slide-level alerts with heatmaps to guide the pathologist to areas likely to contain cancer, acting as a safety net to catch potentially missed cases.
Galen™ Second Read™ (as Ibex Prostate Detect) received 510(k) clearance from the FDA in January 2025, classifying it as a Class II software algorithm device to assist users in digital pathology. This clearance means it's intended to support, not replace, the pathologist's diagnosis and is specifically for use with slide images digitized by Philips Ultra Fast Scanners.
While effective as a second-read safety net, Galen™ Second Read™ has some limitations. It is currently cleared for use only with Philips Ultra Fast Scanners. Additionally, while it improves sensitivity in detecting missed cancers, studies have shown a slight decrease in overall specificity when pathologists use the device compared to standard of care, meaning it may generate more prompts for review.
Yes, other AI solutions exist in oncology pathology, such as Paige Prostate. Galen™ Second Read™ distinguishes itself by operating specifically on cases already diagnosed as benign, acting as a safety net to catch missed cancers, whereas other solutions like Paige Prostate may provide a binary classification (suspicious/not suspicious) for all cases.
Clinical studies have demonstrated Galen™ Second Read™'s effectiveness. In a retrospective study of initially benign-diagnosed cases, pathologists using the software achieved a sensitivity of 36.3% in catching cancers that would have otherwise been missed. The system has shown a positive predictive value of 99.6% for heatmap accuracy and was able to identify 13% of prostate cancer cases missed by pathologists in initial diagnoses, which were subsequently confirmed.

Related Tools

VERITON CT 400 Series Digital SPECT/CT System (VERITON CT 416/464)
Spectrum Dynamics Medical
Oncology AI
The VERITON CT 400 Series is a digital SPECT/CT system with a 360-degree gantry and 12 swiveling CZT detectors, offering high sensitivity and quantitative accuracy for a wide range of nuclear medicine applications, including advanced theranostics imaging.
syngo.via MI Workflows, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, syngo MBF is an intelligent, integrated imaging software that helps address the challenges of interpreting, managing, and sharing complex data from molecular imaging scanners, providing automated workflows and advanced visualization for various clinical applications.
syngo.via MI WorkFlows, Scenium, syngo MBF
Siemens Medical Solutions USA
Cardiology AI
syngo.via MI Workflows, Scenium, and syngo MBF are medical diagnostic post-processing applications for viewing, manipulation, quantification, analysis, and comparison of PET or nuclear-medicine functional data with CT or MR anatomical data across timepoints, supporting disease management and radiotherapy treatment planning by trained healthcare professionals.
BIOGRAPH One
Siemens Healthineers AG
Oncology AI
BIOGRAPH One is a second-generation PET/MR scanner designed to transform PET/MR image quality for a new era, combining high PET precision with powerful MR performance. It enables simultaneous visualization of organ location, function, and cellular metabolism, offering faster image acquisition times and more efficient workflows than previous generations of PET/MR scanners.
Claire™ OCT System
Perimeter Medical Imaging AI
Oncology AI
Perimeter Medical Imaging AI is a medical technology company driven to transform cancer surgery with ultra-high resolution, real-time, advanced imaging tools that address unmet medical needs.S. for intraoperative breast cancer margin assessment.
syngo.via RT Image Suite VC10
Varian Medical Systems, Inc.
Clinical Decision Support & Reference
syngo.via RT Image Suite VC10 offers advanced imaging and workflow solutions for precise and efficient radiation therapy planning.

See all Oncology AI tools →

Suggest an Edit → | Report an issue | Last Verified: 2026-11-08 | First Added: 2026-04-18

Investors who backed Galen Second Read

Funded through the company that built this tool.

AI Tool Finder
AI-powered search. Results may not be comprehensive.